NCT01027013已完成2 期
A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo for the Treatment of Keratoconjunctivitis Sicca (Dry Eye)
Kubota Vision Inc.5 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 220
- 试验地点
- 5
- 主要终点
- Primary ocular discomfort
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years and older
- •Diagnosis of dry eye as defined by the protocol
排除标准
- •Ongoing ocular disease that may interfere with study parameters.
- •Inability to stop using topical ophthalmic medications throughout the duration of the study
- •Inability to stop the use of contact lenses for the duration of the study.
研究组 & 干预措施
rebamipide 2% ophthalmic suspension
Experimental
干预措施: rebamipide 2% ophthalmic suspension (Drug)
Placebo eye drops
Placebo Comparator
干预措施: placebo eye drops (Drug)
结局指标
主要结局
Primary ocular discomfort
时间窗: 4 weeks
Total fluorescein corneal staining score
时间窗: 4 weeks
次要结局
- Dry eye symptoms(12 weeks)
- Ocular staining(12 weeks)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central CorneaDry EyeKeratoconjunctivitis SiccaNCT01057147Kubota Vision Inc.116
已完成
2 期
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type PsoriasisPsoriasisNCT00230529Centocor, Inc.249
已完成
3 期
A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPDCOPDChronic Obstructive Pulmonary DiseaseNCT00056264Centocor, Inc.234
已完成
2 期
Monotherapy With Rapamycin in Long-standing Type 1 DiabetesDiabetes Mellitus, Type 1NCT02803892Piemonti Lorenzo55
终止
2 期
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19COVID-19NCT04410354ViralClear Pharmaceuticals, Inc.44